RU2018105985A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018105985A3 RU2018105985A3 RU2018105985A RU2018105985A RU2018105985A3 RU 2018105985 A3 RU2018105985 A3 RU 2018105985A3 RU 2018105985 A RU2018105985 A RU 2018105985A RU 2018105985 A RU2018105985 A RU 2018105985A RU 2018105985 A3 RU2018105985 A3 RU 2018105985A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562193348P | 2015-07-16 | 2015-07-16 | |
| US62/193,348 | 2015-07-16 | ||
| US201562204495P | 2015-08-13 | 2015-08-13 | |
| US62/204,495 | 2015-08-13 | ||
| PCT/US2016/042798 WO2017011831A1 (en) | 2015-07-16 | 2016-07-18 | A novel approach for treatment of cancer using immunomodulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019144144A Division RU2817047C2 (ru) | 2015-07-16 | 2016-07-18 | Новый подход к лечению рака с применением иммуномодуляции |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018105985A3 true RU2018105985A3 (enExample) | 2019-08-16 |
| RU2018105985A RU2018105985A (ru) | 2019-08-16 |
| RU2711380C2 RU2711380C2 (ru) | 2020-01-16 |
Family
ID=57757732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018105985A RU2711380C2 (ru) | 2015-07-16 | 2016-07-18 | Новый подход к лечению рака с применением иммуномодуляции |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11564986B2 (enExample) |
| EP (1) | EP3322448A4 (enExample) |
| JP (1) | JP7032311B2 (enExample) |
| KR (1) | KR20180036974A (enExample) |
| CN (3) | CN108136025B (enExample) |
| AU (3) | AU2016293674B2 (enExample) |
| BR (1) | BR112018000917A2 (enExample) |
| CA (1) | CA2991628C (enExample) |
| HK (1) | HK1248115A1 (enExample) |
| MA (1) | MA42459A (enExample) |
| MX (2) | MX2018000619A (enExample) |
| NZ (1) | NZ739503A (enExample) |
| RU (1) | RU2711380C2 (enExample) |
| WO (1) | WO2017011831A1 (enExample) |
| ZA (2) | ZA201800688B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016019232A1 (en) | 2014-08-01 | 2016-02-04 | John Vasilakos | Methods and therapeutic combinations for treating tumors |
| JP7032311B2 (ja) | 2015-07-16 | 2022-03-08 | バイオエクセル セラピューティクス，インコーポレイテッド | 免疫調節を使用してがんを処置するための新規手法 |
| CN108883107A (zh) | 2015-12-24 | 2018-11-23 | 科尔沃斯制药股份有限公司 | 治疗癌症的方法 |
| KR102557900B1 (ko) | 2016-09-07 | 2023-07-19 | 트러스티즈 오브 터프츠 칼리지 | 면역-dash 억제제와 pge2 길항제를 이용한 병행 요법 |
| MX2019003755A (es) * | 2016-10-06 | 2019-08-12 | Pfizer | Regimen de dosificacion de avelumab para el tratamiento de cancer. |
| US11613785B2 (en) | 2017-01-09 | 2023-03-28 | Onkosxcel Therapeutics, Llc | Predictive and diagnostic methods for prostate cancer |
| MX2019011749A (es) * | 2017-03-28 | 2020-01-23 | Dicerna Pharmaceuticals Inc | Reduccion de la expresion de beta-catenina para potenciar la inmunoterapia. |
| EP3606531A4 (en) | 2017-04-04 | 2021-04-28 | Corvus Pharmaceuticals, Inc. | METHOD OF TREATMENT OF CANCER |
| US11559537B2 (en) | 2017-04-07 | 2023-01-24 | Trustees Of Tufts College | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists |
| CA3082117A1 (en) * | 2017-11-13 | 2019-05-16 | Bioxcel Therapeutics, Inc. | Methods and compositions for treating cancer by modifying multiple arms of the immune system |
| IL275333B2 (en) * | 2017-12-15 | 2023-09-01 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| WO2019202473A1 (en) * | 2018-04-16 | 2019-10-24 | Université de Lausanne | Ucp2 inducing agents for the treatment of cancer resistant to immune checkpoint blockade |
| WO2020069408A1 (en) * | 2018-09-28 | 2020-04-02 | Canimguide Therapeutics Ab | Pharmaceutical formulations of peptide inhibitors |
| GB201819853D0 (en) * | 2018-12-05 | 2019-01-23 | Innovation Ulster Ltd | Therapy |
| WO2020123477A1 (en) * | 2018-12-10 | 2020-06-18 | Bioxcel Therapeutics, Inc. | Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist |
| JP2022512158A (ja) * | 2018-12-10 | 2022-02-02 | バイオエクセル セラピューティクス，インコーポレイテッド | 免疫調節を使用したがんの治療のための新規アプローチ |
| US11504364B2 (en) | 2018-12-21 | 2022-11-22 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| JP7543278B2 (ja) | 2019-01-07 | 2024-09-02 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| US20230338402A1 (en) * | 2020-02-07 | 2023-10-26 | Bioxcel Therapeutics, Inc. | Treatment regimen for cancer using immunomodulation |
| CA3167994A1 (en) * | 2020-02-14 | 2021-08-19 | Bioxcel Therapeutics, Inc. | Systems and methods for detection and prevention of emergence of agitation |
| US12097213B2 (en) * | 2020-03-13 | 2024-09-24 | The Board Of Regents Of The University Of Texas System | Sequential treatment of cancers using 6-thio-dG, checkpoint inhibitors and radiation therapy |
| EP4147053A1 (en) * | 2020-05-07 | 2023-03-15 | Institut Curie | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
| US20220257759A1 (en) * | 2021-02-17 | 2022-08-18 | Bioxcel Therapeutics, Inc. | Treatment of sarcoma using immunomodulation |
| WO2023172958A1 (en) * | 2022-03-08 | 2023-09-14 | Onkosxcel Therapeutics, Llc | Stable formulations of talabostat |
| MX2024010993A (es) * | 2022-03-11 | 2024-09-17 | Intra Cellular Therapies Inc | Compuestos organicos. |
| WO2024107832A2 (en) * | 2022-11-16 | 2024-05-23 | Onkosxcel Therapeutics, Llc | Treatment regimen for treating cancers |
| WO2024155790A2 (en) * | 2023-01-18 | 2024-07-25 | Onkosxcel Therapeutics, Llc | Novel approach for treatment of cancer using immunomodulation |
| WO2025076445A1 (en) * | 2023-10-04 | 2025-04-10 | Agenus Inc. | Anti-fap antibodies and methods of use thereof |
| CN117482249B (zh) * | 2023-11-28 | 2024-09-17 | 辽宁中医药大学 | 一种肝癌干细胞niche响应型逐级靶向脂质体及其应用 |
| CN117695397A (zh) * | 2024-02-06 | 2024-03-15 | 北京肿瘤医院(北京大学肿瘤医院) | 用于提高肿瘤靶向cldn18.2治疗疗效的药物 |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6825169B1 (en) | 1991-10-22 | 2004-11-30 | Trustees Of Tufts College | Inhibitors of dipeptidyl-aminopeptidase type IV |
| FR2703251B3 (fr) | 1993-03-31 | 1995-08-04 | Vacsyn Sa | Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine . |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
| US6979697B1 (en) | 1998-08-21 | 2005-12-27 | Point Therapeutics, Inc. | Regulation of substrate activity |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| CA2356215C (en) | 1998-12-23 | 2015-11-24 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
| US6890904B1 (en) * | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
| WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| WO2001054732A1 (en) | 2000-01-27 | 2001-08-02 | Genetics Institute, Llc. | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| JP4249013B2 (ja) | 2001-07-31 | 2009-04-02 | 佑 本庶 | Ｐｄ−１に対し特異性を有する物質 |
| BR0309254A (pt) | 2002-04-12 | 2005-03-01 | Medarex Inc | Uso de um anticorpo anti-ctla-4 |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| EP1793858A4 (en) | 2004-09-08 | 2008-12-10 | Univ Ohio State Res Found | HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT |
| DK2161336T4 (en) | 2005-05-09 | 2017-04-24 | Ono Pharmaceutical Co | Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies |
| RS54271B1 (sr) | 2005-07-01 | 2016-02-29 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1) |
| EP1909758A1 (en) | 2005-08-02 | 2008-04-16 | I.D.M. Immuno-Designed Molecules | Process for the preparation of liposomal formulations |
| WO2007058957A2 (en) | 2005-11-10 | 2007-05-24 | Point Therapeutics, Inc | Boroproline compound and cytokine combination therapy |
| WO2007059099A2 (en) | 2005-11-14 | 2007-05-24 | Point Therapeutics, Inc. | Boroproline combination therapy for cancer |
| AU2007239095B2 (en) | 2006-01-09 | 2012-05-03 | The Regents Of The University Of California | Immunostimulatory combinations for vaccine adjuvants |
| WO2007127204A2 (en) * | 2006-04-24 | 2007-11-08 | Dara Biosciences, Inc. | Methods and compositions relating to immunostimulation |
| WO2008033368A2 (en) | 2006-09-12 | 2008-03-20 | Dara Biosciences, Inc. | Boroproline compound and cytokine combination therapy |
| WO2008066729A2 (en) * | 2006-11-22 | 2008-06-05 | Dara Biosciences, Inc. | Boronic acid containing compositions |
| US8603978B2 (en) | 2006-12-01 | 2013-12-10 | The United States of America, as represented by the Secretary, Department of Health and Humand Services | Use of muramyl dipeptide (MDP) for treating inflammation |
| ES2687270T3 (es) | 2007-04-12 | 2018-10-24 | The Brigham And Women's Hospital, Inc. | Fijación como objetivo de ABCB5 para la terapia del cáncer |
| NZ582150A (en) | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| CN101909693A (zh) | 2008-01-08 | 2010-12-08 | 百时美施贵宝公司 | 用于治疗增殖性疾病的抗-ctla4抗体与微管蛋白调节剂的组合 |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| EP2342229A1 (en) | 2008-09-12 | 2011-07-13 | ISIS Innovation Limited | Pd-1 specific antibodies and uses thereof |
| AU2009290543B2 (en) | 2008-09-12 | 2015-09-03 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| MX2011003195A (es) | 2008-09-26 | 2011-08-12 | Dana Farber Cancer Inst Inc | Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos. |
| WO2010065711A1 (en) | 2008-12-04 | 2010-06-10 | Adimab, Inc. | An abcb5 epitope and antibodies thereto for the treatment of cancer |
| HRP20170908T1 (hr) | 2008-12-09 | 2017-09-22 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| GB0903325D0 (en) | 2009-02-26 | 2009-04-08 | Univ Aberdeen | Antibody molecules |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| IL323000A (en) | 2010-03-05 | 2025-10-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeted for immune modulation |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
| EP2545073B1 (en) | 2010-03-12 | 2015-09-30 | AbbVie Biotherapeutics Inc. | Ctla4 proteins and their uses |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2012062218A1 (en) | 2010-11-11 | 2012-05-18 | The University Of Hong Kong | Soluble pd-1 variants, fusion constructs, and uses thereof |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| RU2013149800A (ru) * | 2011-04-08 | 2015-05-20 | Афраксис Холдингз, Инк. | 8-этил-6-(арил)пиридо[2,3-d]пиримидин-7(8h)-оны для лечения расстройств нервной системы и рака |
| AU2012290121B2 (en) | 2011-08-01 | 2015-11-26 | Genentech, Inc. | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors |
| HK1201871A1 (en) * | 2011-11-22 | 2015-09-11 | Trustees Of Tufts College | Small molecule enhancer for dendritic cell cancer vaccines |
| RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
| CA2873402C (en) | 2012-05-15 | 2023-10-24 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| US9376437B2 (en) * | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
| US10150800B2 (en) * | 2013-03-15 | 2018-12-11 | Zyngenia, Inc. | EGFR-binding modular recognition domains |
| HRP20210122T1 (hr) | 2013-05-02 | 2021-04-16 | Anaptysbio, Inc. | Protutijela usmjerena protiv programirane smrti-1 (pd-1) |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| SG11201601844TA (en) | 2013-09-13 | 2016-04-28 | Beigene Ltd | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| CN104558177B (zh) | 2013-10-25 | 2020-02-18 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途 |
| JP2016540042A (ja) * | 2013-11-05 | 2016-12-22 | コグネート バイオサービシズ， インコーポレイテッド | がんを処置するためのチェックポイント阻害剤および治療薬の組合せ |
| EP3066125A2 (en) * | 2013-11-06 | 2016-09-14 | Boehringer Ingelheim International GmbH | Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents |
| BR112016013963A2 (pt) | 2013-12-17 | 2017-10-10 | Genentech Inc | terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1 |
| EP3082853A2 (en) * | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| BR112016014284A2 (pt) | 2013-12-20 | 2017-12-05 | Intervet Int Bv | anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo |
| PL3466949T3 (pl) * | 2013-12-24 | 2021-05-31 | Bristol-Myers Squibb Company | Związek tricykliczny jako środki przeciwrakowe |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| BR112016018521A2 (pt) | 2014-02-14 | 2017-10-17 | Immune Design Corp | composição, e, kit. |
| SI3134123T1 (sl) | 2014-02-21 | 2021-08-31 | Nektar Therapeutics (India) Pvt. Ltd. | IL-2Rbeta-selektivni agonisti v kombinaciji s protitelesom proti- CTLA-4 ali protitelesom proti-PD-1 |
| CN105330740B (zh) | 2014-07-30 | 2018-08-17 | 珠海市丽珠单抗生物技术有限公司 | 抗pd-1抗体及其应用 |
| JP6680760B2 (ja) | 2014-07-31 | 2020-04-15 | アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ | アンタゴニストｉｃ ｐｄ−１アプタマー及びその癌治療関連用途への応用 |
| ES2819451T3 (es) | 2014-08-08 | 2021-04-16 | Univ Leland Stanford Junior | Agentes PD-1 de alta afinidad y procedimientos de uso |
| DK3179992T3 (da) * | 2014-08-11 | 2022-07-11 | Acerta Pharma Bv | Terapeutisk kombination af en btk-inhibitor, en pd-1-inhibitor og/eller en pd-l1-inhibitor |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| EP3206711B1 (en) | 2014-10-14 | 2023-05-31 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| EP3218409A2 (en) | 2014-11-11 | 2017-09-20 | Sutro Biopharma, Inc. | Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies |
| US20160148513A1 (en) | 2014-11-20 | 2016-05-26 | Here Global B.V. | Method and apparatus for providing line-of-sight obstruction notification for navigation |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| CA2971734C (en) | 2014-12-22 | 2025-11-18 | Enumeral Biomedical Holdings Inc | Anti-pd-1 antibodies |
| CN104479020B (zh) | 2014-12-26 | 2019-08-02 | 上海复宏汉霖生物技术股份有限公司 | 一种抗pd-1人源抗体 |
| IL292578A (en) | 2015-02-13 | 2022-06-01 | Sorrento Therapeutics Inc | Antibody therapeutics that bind ctla4 |
| CN104761633B (zh) | 2015-03-25 | 2018-11-27 | 新乡学院 | 阻断猪pd-1/pd-l1通路的多肽及其应用 |
| WO2016179576A1 (en) | 2015-05-07 | 2016-11-10 | Bioxcel Corporation | Novel immunomodulatory therapeutic strategies targeting tumors in cancer |
| MX2017015937A (es) | 2015-06-08 | 2018-12-11 | Genentech Inc | Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1. |
| CN105061597B (zh) | 2015-06-09 | 2016-04-27 | 北京东方百泰生物科技有限公司 | 一种抗pd-1的单克隆抗体及其获得方法 |
| KR102712880B1 (ko) | 2015-06-16 | 2024-10-02 | 메르크 파텐트 게엠베하 | Pd-l1 길항제 조합 치료 |
| JP7032311B2 (ja) | 2015-07-16 | 2022-03-08 | バイオエクセル セラピューティクス，インコーポレイテッド | 免疫調節を使用してがんを処置するための新規手法 |
| WO2017020974A1 (en) | 2015-08-03 | 2017-02-09 | Institut Pasteur | Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy |
| WO2017040670A1 (en) | 2015-09-01 | 2017-03-09 | Ifm Therapeutics, Inc | Immune cells having increased immunity or resistance to an immunosuppressive cytokine and use of the same |
| WO2017058881A1 (en) | 2015-09-28 | 2017-04-06 | The Trustees Of Columbia University In The City Of New York | Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma |
| IL316210A (en) | 2015-10-01 | 2024-12-01 | Heat Biologics Inc | Compounds and methods for connecting type 1 and 2 extracellular complexes as heterologous chimeric proteins |
| CN105175544B (zh) | 2015-10-20 | 2021-04-09 | 安徽瀚海博兴生物技术有限公司 | 一种抗pd-1人源化单克隆抗体及其应用 |
| WO2017079303A1 (en) | 2015-11-02 | 2017-05-11 | The Cleveland Clinic Foundation | Sequentially orchestrated immune checkpoint therapy for the treatment and prevention of cancer |
| CN109312309B (zh) | 2016-01-08 | 2024-04-02 | 雷普利穆内有限公司 | 工程化的病毒 |
| US20190008918A1 (en) | 2016-03-08 | 2019-01-10 | Bioxcel Corporation | Immunomodulation therapies for cancer |
| KR102557900B1 (ko) | 2016-09-07 | 2023-07-19 | 트러스티즈 오브 터프츠 칼리지 | 면역-dash 억제제와 pge2 길항제를 이용한 병행 요법 |
| KR20230114331A (ko) | 2016-09-14 | 2023-08-01 | 애브비 바이오테라퓨틱스 인크. | 항-pd-1 항체 및 이의 용도 |
| US11613785B2 (en) | 2017-01-09 | 2023-03-28 | Onkosxcel Therapeutics, Llc | Predictive and diagnostic methods for prostate cancer |
| CA3082117A1 (en) | 2017-11-13 | 2019-05-16 | Bioxcel Therapeutics, Inc. | Methods and compositions for treating cancer by modifying multiple arms of the immune system |
| JP2022512158A (ja) | 2018-12-10 | 2022-02-02 | バイオエクセル セラピューティクス，インコーポレイテッド | 免疫調節を使用したがんの治療のための新規アプローチ |
| WO2020123477A1 (en) | 2018-12-10 | 2020-06-18 | Bioxcel Therapeutics, Inc. | Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist |
-
2016
- 2016-07-18 JP JP2018521501A patent/JP7032311B2/ja active Active
- 2016-07-18 RU RU2018105985A patent/RU2711380C2/ru active
- 2016-07-18 CN CN201680045055.1A patent/CN108136025B/zh active Active
- 2016-07-18 NZ NZ739503A patent/NZ739503A/en unknown
- 2016-07-18 WO PCT/US2016/042798 patent/WO2017011831A1/en not_active Ceased
- 2016-07-18 BR BR112018000917A patent/BR112018000917A2/pt not_active Application Discontinuation
- 2016-07-18 AU AU2016293674A patent/AU2016293674B2/en active Active
- 2016-07-18 CA CA2991628A patent/CA2991628C/en active Active
- 2016-07-18 CN CN202211308354.3A patent/CN116059219A/zh active Pending
- 2016-07-18 HK HK18107658.8A patent/HK1248115A1/zh unknown
- 2016-07-18 CN CN202211308353.9A patent/CN116059218A/zh active Pending
- 2016-07-18 KR KR1020187003641A patent/KR20180036974A/ko not_active Ceased
- 2016-07-18 EP EP16825310.2A patent/EP3322448A4/en active Pending
- 2016-07-18 MA MA042459A patent/MA42459A/fr unknown
- 2016-07-18 MX MX2018000619A patent/MX2018000619A/es unknown
-
2017
- 2017-03-23 US US15/467,781 patent/US11564986B2/en active Active
-
2018
- 2018-01-12 MX MX2022010270A patent/MX2022010270A/es unknown
- 2018-02-01 ZA ZA2018/00688A patent/ZA201800688B/en unknown
-
2019
- 2019-05-30 ZA ZA2019/03442A patent/ZA201903442B/en unknown
-
2020
- 2020-02-10 AU AU2020200953A patent/AU2020200953B2/en active Active
-
2022
- 2022-03-21 AU AU2022201950A patent/AU2022201950A1/en not_active Abandoned
- 2022-12-21 US US18/069,489 patent/US20240000928A1/en not_active Abandoned
-
2024
- 2024-08-13 US US18/802,908 patent/US20250213681A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020200953B2 (en) | 2021-12-23 |
| CN116059218A (zh) | 2023-05-05 |
| MX2018000619A (es) | 2019-03-06 |
| ZA201800688B (en) | 2020-08-26 |
| RU2019144144A (ru) | 2020-03-19 |
| JP2018521135A (ja) | 2018-08-02 |
| RU2711380C2 (ru) | 2020-01-16 |
| WO2017011831A1 (en) | 2017-01-19 |
| CN108136025A (zh) | 2018-06-08 |
| AU2016293674A1 (en) | 2018-02-22 |
| CN108136025B (zh) | 2022-09-06 |
| HK1248115A1 (zh) | 2018-10-12 |
| AU2016293674B2 (en) | 2019-11-21 |
| US20250213681A1 (en) | 2025-07-03 |
| MX2022010270A (es) | 2022-09-19 |
| EP3322448A4 (en) | 2019-03-06 |
| EP3322448A1 (en) | 2018-05-23 |
| BR112018000917A2 (pt) | 2018-09-11 |
| US20240000928A1 (en) | 2024-01-04 |
| JP7032311B2 (ja) | 2022-03-08 |
| NZ739503A (en) | 2023-06-30 |
| CN116059219A (zh) | 2023-05-05 |
| US20170266280A1 (en) | 2017-09-21 |
| CA2991628A1 (en) | 2017-01-19 |
| MA42459A (fr) | 2018-05-23 |
| AU2020200953A1 (en) | 2020-02-27 |
| KR20180036974A (ko) | 2018-04-10 |
| RU2018105985A (ru) | 2019-08-16 |
| US11564986B2 (en) | 2023-01-31 |
| ZA201903442B (en) | 2021-04-28 |
| AU2022201950A1 (en) | 2022-04-14 |
| CA2991628C (en) | 2020-04-07 |